Evorpacept

Phase 2Protein / enzyme

AALX Oncology Inc.

Evorpacept is one of 239 small molecule programs targeting Oropharynx Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

238

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharynx CancerActive, not recruiting

LymphomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Gastric CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

CancersCompleted

Urothelial CarcinomaActive, not recruiting

Oropharynx CancerPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Gastric CancerPhase 2/Phase 3

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

CancersPreclinical

Completed

Urothelial CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Evorpacept

AALX Oncology Inc.

Phase 2

1 2

Oncaspar

SServier

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

PEG-Intron

Merck & Co.

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Malignancies

NCT07007559

Q2 2028

Phase 1/2Recruiting

Age

NCT04643002

Phase 2Recruiting

Oropharynx Cancer

NCT05787639

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Active, not recruiting·AALX Oncology Inc.·Phase 2·NCT04675294·189 enrolled

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Active, not recruiting·AALX Oncology Inc.·Phase 2·NCT04675333·172 enrolled

Oropharynx Cancer1 trial

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Recruiting·UUniversity of California, San Diego·Phase 2·NCT05787639·29 enrolled

Myelodysplastic Syndrome1 trial

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Terminated·AALX Oncology Inc.·Phase 1·NCT04417517·65 enrolled

Malignancies1 trial

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Recruiting·AALX Oncology Inc.·Phase 1/2·NCT07007559·80 enrolled

Lymphoma1 trial

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Completed·AALX Oncology Inc.·Phase 1·NCT03013218·174 enrolled

6 more indications

Metastatic Colorectal Cancer1 trial

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05167409·48 enrolled

Gastric Cancer1 trial

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Active, not recruiting·AALX Oncology Inc.·Phase 2/3·NCT05002127·127 enrolled

Age1 trial

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT04643002·258 enrolled

Urothelial Carcinoma1 trial

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Completed·AALX Oncology Inc.·Phase 1·NCT05524545·36 enrolled

Acute Myeloid Leukemia1 trial

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Terminated·AALX Oncology Inc.·Phase 1·NCT04755244·14 enrolled

Cancers1 trial

A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Preclinical·NCT05027139·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Evorpacept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Evorpacept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Evorpacept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ALX Oncology Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: AALX Oncology Inc.

Evorpacept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma2 trials

Oropharynx Cancer1 trial

Myelodysplastic Syndrome1 trial

Malignancies1 trial

Lymphoma1 trial

Metastatic Colorectal Cancer1 trial

Gastric Cancer1 trial

Age1 trial

Urothelial Carcinoma1 trial

Acute Myeloid Leukemia1 trial

Cancers1 trial

References

Drug Info

Quick Facts

Related News